
MediWound (MDWD) Stock Forecast & Price Target
MediWound (MDWD) Analyst Ratings
Bulls say
MediWound Ltd's product pipeline, particularly with EscharEx, demonstrates significant revenue potential, projected to grow from $6.2 million in 2027 to $97.4 million by 2030, indicating strong market demand for its innovations in wound care. The company's FDA-approved NexoBrid continues to drive robust revenue, supported by partnerships in the U.S. market and growing institutional adoption, as evidenced by the increasing number of burn centers placing orders. Furthermore, the expected ramp-up of its GMP-compliant manufacturing facility is anticipated to increase production capacity six-fold, positioning MediWound to meet rising demand and enhance its financial performance.
Bears say
MediWound Ltd has lowered its 12-month price target to $25 per diluted share from $28, reflecting a decreased outlook on its financial performance. In the third quarter of 2024, the company reported total revenues of $4.4 million, significantly below the consensus estimate of $6.0 million, coupled with a larger net loss of $0.98 per share compared to an anticipated loss of $0.45 per share. Furthermore, despite management's estimation of a $2.5 billion addressable market for EscharEx, the company's continual financial losses raise concerns regarding its ability to capitalize on this potential.
This aggregate rating is based on analysts' research of MediWound and is not a guaranteed prediction by Public.com or investment advice.
MediWound (MDWD) Analyst Forecast & Price Prediction
Start investing in MediWound (MDWD)
Order type
Buy in
Order amount
Est. shares
0 shares